

**AKSA AKRİLİK KİMYA SANAYİİ A.Ş.**

**CONVENIENCE TRANSLATION INTO ENGLISH OF  
CONSOLIDATED FINANCIAL STATEMENTS  
AT 30 SEPTEMBER 2013**

**(ORIGINALLY ISSUED IN TURKISH)**

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**AKSA AKRİLİK KİMYA SANAYİİ A.Ş.**

**CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE PERIOD ENDED 30 SEPTEMBER 2013**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise indicated.)

	<b>30 September 2013 USD (*)</b>	<b>30 September 2013 TL</b>	<b>31 December 2012 TL</b>
<b>ASSETS</b>			
<b>Current Assets</b>	<b>371.179</b>	<b>755.049</b>	<b>692.258</b>
Cash and cash equivalents	50.700	103.133	141.472
Trade receivable			
- Other trade receivables	122.321	248.825	179.383
- Due from related parties	63.556	129.286	139.091
Other receivables	86	174	170
Inventories	101.125	205.708	164.935
Prepaid expenses	2.863	5.823	2.865
Other current assets	30.528	62.100	64.342
<b>Non-current Assets</b>	<b>450.217</b>	<b>915.834</b>	<b>864.698</b>
Trade receivables	-	-	4.490
Financial investments	652	1.327	1.327
Joint ventures accounted for by the equity method	117.701	239.428	227.742
Property, plant and equipment	316.443	643.709	618.035
Intangible assets	5.168	10.512	4.821
Goodwill	2.944	5.989	5.989
Prepaid expenses	21	44	47
Other non-current assets	7.288	14.825	2.247
<b>TOTAL ASSETS</b>	<b>821.396</b>	<b>1.670.883</b>	<b>1.556.956</b>

(\*) US Dollar (“USD”) amounts presented above have been translated from Turkish Lira (“TL”) for convenience purposes only, at the official TL bid rate announced by the Central Bank of the Republic of Turkey (“CBRT”) at 30 September 2012, and therefore do not form part of these consolidated financial statements.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**AKSA AKRİLİK KİMYA SANAYİİ A.Ş.**

**CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE PERIOD ENDED 30 SEPTEMBER 2013**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

	<b>30 Sep 2013 USD (*)</b>	<b>30 Sep 2013 TL</b>	<b>31 Dec 2012 TL</b>
<b>LIABILITIES</b>			
<b>Current liabilities</b>	<b>244.698</b>	<b>497.765</b>	<b>429.596</b>
Short-term financial liabilities	76.004	154.607	133.859
Short-term portion of long-term financial liabilities	25.026	50.907	36.538
Trade payables			
- Other trade payables	121.826	247.818	215.793
- Due to related parties	9.984	20.310	28.674
Other payables	1.744	3.547	2.992
Unearned revenue	53	107	23
Taxes on income	6.569	13.362	5.902
Provisions	1.839	3.741	4.639
Derivative financial instruments	1.271	2.585	-
Other current liabilities	382	781	1.176
<b>Non-current Liabilities</b>	<b>86.473</b>	<b>175.904</b>	<b>156.440</b>
Financial liabilities	74.622	151.797	129.126
Derivative financial instruments	33	67	1.723
Provision for employment termination benefits	8.017	16.308	16.156
Unearned revenue	198	402	992
Deferred income tax liabilities	3.603	7.330	8.443
Other non-current liabilities	525	950	992
<b>Total Liabilities</b>	<b>331.171</b>	<b>673.669</b>	<b>586.036</b>
<b>EQUITY</b>	<b>490.225</b>	<b>997.214</b>	<b>970.920</b>
<b>Attributable to Equity Holders of the Parent</b>	<b>490.200</b>	<b>997.163</b>	<b>960.623</b>
Share capital	90.945	185.000	185.000
Adjustment to share capital	95.947	195.175	195.175
Share premium	22	44	44
Restricted reserves	40.686	82.764	60.644
Currency translation differences	15.289	31.100	(1.098)
Hedge funds	(234)	(476)	(993)
Actuarial gain/loss	(1.633)	(3.322)	(4.220)
Retained earnings	198.221	403.221	357.562
Net income for the year	50.957	103.657	168.509
<b>Non-controlling Interests</b>	<b>25</b>	<b>51</b>	<b>10.297</b>
<b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b>	<b>821.396</b>	<b>1.670.883</b>	<b>1.556.956</b>

(\*) USD amounts presented above have been translated from Turkish Lira ("TL") for convenience purposes only, at the official TL bid rate announced by the CBRT at 30 September 2013, and therefore do not form part of these consolidated financial statements.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**AKSA AKRİLİK KİMYA SANAYİİ A.Ş.**

**CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE PERIOD ENDED 30 SEPTEMBER 2013**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise indicated.)

	1 January - 30 September 2013 USD (*)	1 January - 30 September 2013 TL	1 July - 30 September 2013 TL	1 January - 30 September 2012 TL	1 July - 30 September 2012 TL
Sales	675.118	1.259.031	459.581	1.233.562	396.262
Cost of sales (-)	(561.213)	(1.046.609)	(378.553)	(1.051.272)	(333.617)
<b>Gross profit</b>	<b>113.905</b>	<b>212.422</b>	<b>81.028</b>	<b>182.290</b>	<b>62.645</b>
Marketing, selling and distribution expenses (-)	(17.836)	(33.262)	(10.564)	(38.065)	(9.739)
General administrative expenses (-)	(13.661)	(25.476)	(10.134)	(25.331)	(8.310)
Research and development expenses (-)	(2.500)	(4.663)	(1.019)	(1.159)	(311)
Other operating income	18.911	35.267	10.657	118.513	7.654
Other operating expenses (-)	(22.871)	(42.653)	(16.496)	(34.153)	(5.100)
<b>Operating profit</b>	<b>75.948</b>	<b>141.635</b>	<b>53.472</b>	<b>202.095</b>	<b>46.839</b>
Share of loss of investment in Joint Venture	(10.196)	(19.014)	(7.106)	(1.417)	(1.417)
Financial income	38.732	72.232	25.861	59.091	9.715
Financial expenses (-)	(30.706)	(57.264)	(19.846)	(46.182)	(7.280)
<b>Profit before tax</b>	<b>73.778</b>	<b>137.589</b>	<b>52.381</b>	<b>213.587</b>	<b>47.857</b>
<b>Taxation expense on income:</b>					
- Income tax expense	(17.969)	(33.511)	(12.755)	(61.664)	(8.967)
- Deferred tax benefit/(charge)	775	1.445	724	2.052	(190)
<b>Net income for the period</b>	<b>56.584</b>	<b>105.523</b>	<b>40.350</b>	<b>153.975</b>	<b>38.700</b>
<b>Other comprehensive income/(expense):</b>					
Remeasurement gain/loss arising from defined benefit plan	602	1.123	-	-	-
Taxation on other comprehensive income not to be classified to profit and loss	(121)	(225)	-	-	-
Changes in fair value of derivative financial instruments	346	646	969	(683)	(1.704)
Currency translation differences	17.265	32.198	13.752	(10.551)	(3.544)
Fair value changes of derivative financial instruments and currency translation differences associated with profit loss statement due to subsidiary share sales	(69)	(129)	(194)	137	341
<b>Total comprehensive income</b>	<b>74.607</b>	<b>139.136</b>	<b>54.877</b>	<b>151.219</b>	<b>33.793</b>
<b>Net income for the period attributable to:</b>					
Equity holders of the parent	55.583	103.657	40.013	151.501	37.742
Non-controlling interests	1.001	1.866	337	2.474	958
	<b>56.584</b>	<b>105.523</b>	<b>40.350</b>	<b>153.975</b>	<b>38.700</b>
<b>Total comprehensive income attributable to:</b>					
Equity holders of the parent	73.606	137.270	54.540	148.745	32.835
Non-controlling interests	1.001	1.866	337	2.474	958
	<b>74.607</b>	<b>139.136</b>	<b>54.877</b>	<b>151.219</b>	<b>33.793</b>
Earnings per share for equity holders of the parent (TL)	0,30	0,56	0,22	0,82	0,20

(\*) USD amounts presented above have been translated from TL for convenience purposes only, at the USD average CBRT bid rates for the period ended 30 September 2013, and therefore do not form part of these consolidated financial statements.